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ABSTRACT
Objectives: Numerous reports suggest that the clinical course of ovarian cancer (OC) in BRCA, including BRCA1, mutation 
carriers (BRCA1-OC) is different than in patients with sporadic ovarian cancer (SOC). Most of the authors indicate more fa-
vourable treatment results in patients with BRCA1-OC. The aim of the study was to compare the effectiveness of treatment 
of patients with advanced-stage (FIGO III/IV) SOC and BRCA1-OC.
Material and methods: Between 2004 and 2009, 957 OC patients were treated in Cracow Branch of Cancer Center, M. 
Sklodowska-Curie Memorial Institute, Poland. Germline BRCA1 mutation was found in 66 patients. To compare the effective-
ness of treatment, the group of 47 advanced-stage BRCA1-OC patients was matched with the group of 47 advanced-stage 
SOC patients. Pairs of patients were matched in terms of the most important prognostic factors, i.e. stages according to 
FIGO, primary cytoreduction extent, tumour histologic subtype and grade, as well as year of diagnosis and treatment.
Results: The 5-year overall survival rate was 42.9% for BRCA1-OC patients and 34.3% for SOC patients (p = 0.354). Mean time 
to progression was 22.7 and 14.5 months for BRCA1-OC and SOC group, respectively (p = 0.05). Complete response to pri-
mary surgery and first line chemotherapy was obtained in 42.5% and 37.9% of cases, respectively; the difference, however, 
did not reach the statistical significance.
Conclusions: Results of combined treatment in the group of BRCA1-related OC patients seem to be better than in the 
group of sporadic ovarian cancer patients.
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INTRODUCTION
Numerous reports suggest that the clinical course of 
OC in BRCA1/2 mutation carriers is different than in women 
with sporadic OC. Most of the authors indicate more favour-
able treatment results in BRCA1/2-related ovarian cancer 
patients; the data, however, were obtained predominantly 
in the American, British and Jewish population [1–5]. It is 
considered that due to the mutation of BRCA1 and BRCA2, 
resulting in DNA repair impairment, BRCA-related cancers 
are more sensitive to cytostatic agents that induce double 
strand DNA breaks, such as cisplatin and carboplatin [6, 7]. 
Only few authors single out BRCA1-OC subgroup from the 
entire BRCA1/2-OC group. Additionally, literature reports 
do not distinguish the advanced-stage (FIGO III/IV) patient 
group. Moreover, except for one paper on 18 BRCA1 muta-
tion carriers, there are no reports on Polish women [8]. It 
seems that genetic differences might induce a different 
clinical course of OC in the Central-European population. 
Data presented in the literature are retrospective and 
compare groups of different number of patient and, some-
times, of non-uniform distribution of demographic, histo-
pathological and clinical features.
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AIM OF THE STUDY
The aim of the study was to compare the effective-
ness of treatment of patients with advanced-stage SOC 
and BRCA1-OC.
MATERIAL AND METHODS 
The report presents the analysis of clinical data in-
cluding 957 patients with OC treated in Cancer Center, 
M. Sklodowska-Curie Memorial Institute, Cracow Branch 
between 2004 and 2009. Based on the family history of he-
reditary breast and ovarian cancer, the group of 249 patients 
was identified. Blood samples were taken from patients, after 
obtaining their written consent, to perform genetic testing 
for germ-line BRCA1 mutation carrier state. Exons 2, 5, 11 and 
20 of BRCA1 were examined. The material was screened for 
BRCA1 mutations, which are the most frequent in the Pol-
ish population, i.e. 4153delA, 5382insC C61G, 185delAG, 
and 3819del5. Genetic testing was performed using dena-
turing high-performance liquid chromatography (dHPLC), 
restriction fragment length polymorphism analysis (RFLP) 
and DNA sequencing, 47 patients with advanced-stage BR-
CA1-OC were selected from 66 BRCA1 carriers and matched 
with 47 SOC patients. Demographic, histopathological and 
clinical characteristics of the studied groups were deter-
mined by pair matching in terms of primary prognostic 
factors including cytoreduction extent, histologic subtype 
(serous vs. non-serous cancers) and tumour histologic grade 
G. The aim of matching was to eliminate, as much as pos-
sible, the influence of other factors than BRCA1 mutation 
that might affect the outcome of the treatment. 
The response to combined treatment (surgery + chemo-
therapy) was evaluated based on the medical examination, 
imaging (RECIST 1.0 criteria) and marker assay (CA125 mark-
er level in blood serum) as well as second-look surgery. All 
the patients were followed up for at least 3 years, unless 
a patient died within that period.
The effectiveness of treatment was evaluated according 
to the time to progression, defined as the period between 
the start of treatment (date of surgery or first cycle of in-
duction chemotherapy) and cancer recurrence confirmed 
by medical or imaging examination, and the overall 5-year 
survival rate calculated from the date of start of treatment. 
The mean follow-up time was 65 months. The survival prob-
ability was estimated using the Kaplan-Meier method [9]. 
The Peto log-rank test was used to evaluate the statistical 
significance of differences in observed results [10]. The sta-
tistical significance level was set at p ≤ 0.05.
RESULTS
Demographic, histopathological and clinical charac-
teristics of the group of 47 pairs of patients with advanced 
BRCA1-OC and SOC are presented in Table 1.
Patients with menopause constituted 55.3% of both 
BRCA1-OC and SOC groups. The mean age of patients was 
48.2 and 54.2 years, respectively. The optimal cytoreduc-
tion (defined as residual disease < 1 cm) was obtained in 
21 (44.7%) patients in each of the groups. In accordance with 
the international recommendations, all the patients were 
given platinum-based chemotherapy. Paclitaxel + platinum 
regimen, considered currently to be the “gold standard” 
for OC adjuvant treatment, was applied in 33 (70.2%) and 
31 (65.9%) cases, respectively. No statistically significant dif-
ferences were observed between the two groups in regard 
to applied chemotherapy regimens.
The 5-year survival rate was 42.9% for BRCA1-OC patients 
and 34.39% for SOC patients. The difference in the survival 
rate was not statistically significant (p = 0.354). Predicted 
overall survival rates for both groups are presented in Figure 1.
Table 1. Demographic, histopathological and clinical characteristics 
in the group of 47 patient pairs with advanced BRCA1-OC and SOC
Demographic, 
histopathological and 
clinical characteristics
Patients with 
BRCA1-OC
n = 47
Patients 
with SOC
n = 47
P 
value
Patient age
< 50 years 18 (38.3%) 19 (40.4%)
> 50 years 29 (61.7%) 28 (59.6%) 0.833
Menopause
Yes 26 (55.3%) 26 (55.3%)
No 21 (44.7%) 21 (44.7%) 1
Body mass index
< 25 24 (51.1%) 27 (57.4%)
25–30 16 (34%) 15 (31.9%)
> 30 7 (14.9%) 7 (14.9%) 0.763
BRCA1 mutation type
5382insC 16 (34%) –
189delAG 2 (4.3%)
C61G 27 (57.4%)
Other 2 (4.3%) n/a
Coexisting breast cancer 6 (12.8%) 0 0.011
Tumour histologic grade
G1 2 (4.2%) 1 (2.1%)
G2 13 (27.7%) 14 (29.8%)
G3 32 (68.1%) 32 (68.1%) 0.831
Cancer histologic subtype
Serous 21 (44.7%) 21 (44.7%)
Endometrioid 11 (23.4%) 11 (23.4%)
Mucinous 8 (17%) 8 (17%)
Other 7 (14.9%) 8 (17%) 1
Cytoreduction extent
Optimal 21 (44.7%) 21 (44.7%)
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Table 2 presents treatment outcome comparison be-
tween both groups of patients in regard to the 5-year sur-
vival rate, median survival time, time to progression and 
response to combined treatment.
In 38 women with BRCA1-OC, disease progression was 
observed within the abdominal cavity and, in 3 cases, also 
within the pleural cavity. In the SOC group, disease recur-
rence was observed in 40 patients; it was located within 
the abdominal cavity and, in 4 cases, also within the pleural 
cavity. The recurrence rate for patients with complete remis-
sion of the examined BRCA1-OC and SOC groups (20 and 
15 women, respectively) was 75% and 66%, respectively.
DISCUSSION
The presented report is the analysis of the biggest, so far, 
group of East Central European patients with BRCA1-OC. In 
the literature, there are no prospective studies comparing 
treatment outcome of BRCA1-OC and SOC patients; addi-
tionally, available data do not focus on the advanced-stage 
OC, but also include early-stage cases of a definitely more 
favourable prognosis.
Tan et al. in their report from 2008, matched 
1:2 22 BRCA1/2-OC patients with 44 SOC women for FIGO 
stage, histologic subtype, and age in the year of diagno-
sis [1]. They showed statistically significant differences in 
the response to the second and third line platinum-based 
chemotherapy, longer treatment free interval (TFI) between 
subsequent chemotherapy cycles, and higher 5-year overall 
survival rates in patients with BRCA1/2-OC compared to 
SOC patients. More importantly, the authors showed that 
there were no differences in the response to non-platinum 
agents in any of the 3 chemotherapy cycles. However, the 
analysis was based on a small number of patients. Results 
of no statistical doubt were reported by Zweemer et al. in 
2001, who compared the group of 44 BRCA1/2-OC patients 
with the group of matched 176 SOC cases. The difference in 
median survival was 21.5 months and in the 5-year survival 
rate was 6,1% in favour of patients with BRCA1-OC [3].
In this report, as compared to the literature data, pair 
matching criteria were extended to include cytoreduction 
extent (optimal < 1 cm or sub-optimal ≥ 1 cm) and tu-
mour histologic grade so as to eliminate other significant 
prognostic factors that might influence the outcome of the 
treatment. The distribution of applied adjuvant chemo-
therapy regimens (platinum-based agent + paclitaxel and 
platinum-based agent + another cytostatic) was also similar 
in both groups. The obtained outcome of the treatment, 
however, is ambiguous due to the lack of statistical signifi-
cance of the majority of the results; however, a distinct trend 
suggesting more favourable prognosis for BRCA1-OC pa-
tients has been observed. Only time to progression proved 
to be statistically longer by 8.2 months in BRCA1-OC patients 
(22.7 months vs. 14.5 months, p < 0.05).The number of cases 
without complete remission after combined therapy was 
lower in the group of BRCA1-OC patients than in the SOC 
group, 27 (67.5%) vs. 32 (76.2%) cases, respectively, which 
might indicate a better response to platinum-based che-
motherapy and is consistent with literature reports [11–14].
A better response to chemotherapy in terms of complete 
remission rate in BRCA1-OC patients as compared to SOC 
patients was also observed by Cass et al., Majdak et al. in turn 
reported lower, compared to this report, complete patho-
logical remission in women with BRCA1-OC. No differences 
in response to chemotherapy was also observed in a large 
Norwegian follow-up study [8, 11, 15]. 
Results of the discussed studies were mostly based on 
the Jewish, American and British, or Scandinavian popula-
tion data. The literature lacks reports on patients of East Cen-
tral Europe origin, different in genetic regard as mentioned 
before. The only report on the outcome of the treatment in 
Polish BRCA1-OC patients was presented in 2005 by Majdak 
et al.; however, it included only 18 cases [8].
Table 2. Treatment outcome of BRCA1-OC and SOC patients
Parameter BRCA1-OCn = 47
Sporadic OC
n = 47 P value
5-year overall survival rate 42.90% 34.30% 0.35
Median survival time 
(months) 49 48 0.09
Mean time to progression 
(months) 22.7 14.5 0.05
Treatment response — CR 
(complete response) 20 (42.50%) 15 (31.90%) 0.28
Figure 1. Cumulative survival rate of patients with advanced OC 
according to BRCA1 mutation carrier state
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Results presented in the report should be analysed, tak-
ing into account limitations of the study material. Firstly, the 
retrospective character of the data does not allow to draw 
general conclusions and generates limitations regarding 
data accuracy. Secondly, the number of patients in both 
groups is limited, which does not allow to reach, for example, 
statistical significance of overall 5-year survival rate in spite 
of the evident difference in Kaplan-Meier curves. Thirdly, 
a part of the group was treated using older chemotherapy 
regimens without taxanes. Fourthly, the group of BRCA1-OC 
patients included 6 (12.8%) cases with earlier breast cancer, 
which might had worsened the prognosis. And finally, a rela-
tively small percentage of patients had complete remission 
after combined treatment, which might be due to the high 
rate of second-look surgeries (14.9% in total) confirming 
residual microscopic disease or due to too optimistic de-
scription of the debulking that is widely discussed in the 
literature regarding extent of surgical treatment in OC [16].
CONCLUSIONS
To conclude, the differences in the treatment out-
come between two analysed groups of patients are am-
biguous. The only parameter of statistical significance 
(p = 0.05) suggesting more favourable treatment outcome 
in advanced-stage BRCA1-OC patients was mean time to 
progression. Other parameters proved no statistical signifi-
cance in spite of a distinct trend toward better treatment 
outcome in the group of BRCA1-OC patients.
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